| Non-RA n = 31 | RA-overlapping n = 41 | p value | OR# (95% CI) |
---|---|---|---|---|
Age, median (IQR), years | 59.0 (41.5–68.0) | 64.0 (52.0–69.0) | 0.30 | ND |
Women, % | 87.1 | 92.7 | 0.45 | 1.86 (0.29–13.7) |
Duration of CTD, median (IQR), years | 10.0 (6.0–16.0) | 14.0 (8.0–21.5) | 0.25 | ND |
Arthritis | 18 (58%) | 41 (100%) | 2.9 × 10−6 | Inf (5.9 Inf) |
Bone erosion | 0/25 (0%) | 29/41 (70.7%) | 1.4 × 10−9 | Inf (12.9 Inf) |
RF(+ve/−ve) | 18/10 (64%) | 40/1 (98%) | 3.1 × 10−4 | 21.2 (2.7–982) |
Titer of aCCP†, median (IQR), U/mL | 29.4 (7.9–100) | 72.6 (32.2–100) | 0.045 | ND |
Negative conversion of aCCP | 6/28 (21.4%) | 5/36 (13.9%) | 0.51 | 0.60 (0.13–2.7) |
Usage of DMARDs | 18 (58.1%) | 37 (90.2%) | 2.0 × 10−3 | 6.49 (1.69–31.3) |
Usage of a medium dose of glucocorticoids‡ | 21 (67.7%) | 18 (43.9%) | 0.06 | 0.38 (0.12–1.09) |
HLA-DRB1 SE§ | 6/22 (27.2%) | 20/32 (62.5%) | 0.014 | 4.3 (1.20–17.5) |